ClinicalTrials.gg
Not yet recruitingNCT07639632ReIMageUpdated Jun 12, 2026

Reduce Inefficiencies in Management of Spasticity

An interventional study of Screener and Standard of care in Stroke, sponsored by The University of Texas Health Science Center, Houston. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by The University of Texas Health Science Center, Houston · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies in Stroke by The University of Texas Health Science Center, Houston — 6 open to participants now, 9 under way, none of them phase 3. Stroke · The University of Texas Health Science Center, Houston.

Planned enrollment
7th of 35
80 · median 21
Started
2026
with 4 others
No phase
25 of 39
5 open now
Registered
37th of 39
by date

Among the 39 studies in Stroke by The University of Texas Health Science Center, Houston, this one is the 7th largest by planned enrollment of the 35 interventional ones that give a count, is one of 5 that started in 2026, is one of 25 with no phase, and was the 37th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

6 of the 39 studies in Stroke by The University of Texas Health Science Center, Houston are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Stroke by The University of Texas Health Science Center, Houston, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effectiveness of a spasticity screener and to determine if the spasticity screener results are useful to healthcare providers and impact clinical decision making

03

Conditions studied

  • Stroke

Keywords

  • acute ischemic stroke
  • intracerebral hemorrhage
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Currently admitted for an acute hemorrhagic or ischemic stroke; recurrent stroke allowed if no spasticity at baseline
  • NIHSS score of > 0 on items 5 or 6 (required of at least 1 limb)
  • Willingness to participate in the study for 24 months
  • Able to sign consent form or availability of a legally authorized representative to sign
  • Able to read/write in English
  • Identified MD for follow up post hospitalization

Exclusion criteria

Exclusion Criteria:

  • Botulinum toxin use for any indication within the past 12 weeks
  • Acute life threatening illness
  • Prior limb injury or neurological diagnosis that limited movement in the now affected limb(s)
  • Any terminal illness that would limit participation in study follow ups
  • Known spasticity or other movement disorders that impact tone
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Screener

    Other: Screener

  • Active comparator
    Standard of care

    Other: Standard of care

Interventions

  • OtherScreener

    Participants will be screened for spasticity using the 2 question version of the Post-stroke Spasticity Monitoring Questionnaire (PSMQ) at 2 days after discharge, 2 weeks post stroke, 1 month post stroke, 3 months post stroke and every 3 months after for a total of 12 screenings across 24 months

  • OtherStandard of care

    Observational data for the standard of care group will be obtained via phone every 3 months post stroke up to 24 months, utilizing the Standard of Care Group Questionnaire.

06

What researchers measure

Primary outcomes

  1. Time to detect spasticity from incidence of stroke

    Time frame: From baseline to 24 months after stroke

Secondary outcomes

  1. Time to referral for spasticity from incidence of stroke

    Evaluate average time to referral to neurology or Physical Medicine \& Rehabilitation (PM\&R)

    Time frame: From baseline to 24 months after stroke

  2. The time from incidence of stroke to Botulinum neurotoxin (BoNT) administration

    Time frame: From baseline to 24 months after stroke

07

Study locations

1 site
  • The University of Texas Health Science Center at Houston PO Box 20036
    Houston, Texas 77030, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Aug 2029, 37 months later.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 37 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2026
First posted
Jun 10, 2026
StartEst.
Jun 15, 2026
Primary completionEst.
Aug 1, 2029
CompletionEst.
Nov 30, 2029
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07639632
Collaborators
AbbVie
Responsible party
Sean Savitz (Professor, The University of Texas Health Science Center, Houston) — Principal investigator
First posted
Jun 10, 2026
Start date
Jun 15, 2026 (estimated)
Primary completion
Aug 1, 2029 (estimated)
Completion
Nov 30, 2029 (estimated)
Last update
Jun 12, 2026

Study contacts

Sean I Savitz, MD
Contact
Sean.I.Savitz@uth.tmc.edu
(713) 500-7083
Harriet Sales
Contact
harriet.mari.sales@uth.tmc.edu
(713) 500-7037
Sean I Savitz, MD
principal investigator · The University of Texas Health Science Center at Houston PO Box 20036

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion